eCommons@AKU
Department of Biological & Biomedical Sciences

Medical College, Pakistan

August 2019

Suppressor of cytokine signaling-3 in pregnant
females with or without hypertension
Huma Shoukat Ali
Aga Khan University

Mubeen Ali
Aga Khan University

Sabah Farhat
Aga Khan University, sabah.farhat@aku.edu

Syeda Sadia Fatima
Aga Khan University, sadia.fatima@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs
Part of the Life Sciences Commons
Recommended Citation
Ali, H. S., Ali, M., Farhat, S., Fatima, S. S. (2019). Suppressor of cytokine signaling-3 in pregnant females with or without hypertension.
JPMA. The Journal of the Pakistan Medical Association, 69(8), 1230-1233.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/786

1230

STUDENTS’ CORNER
SHORT COMMUNICATION
Suppressor of cytokine signaling-3 in pregnant females with or without
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Abstract
Suppression of Cytokine Signalling-3 (SOCS-3) modulates
the inflammatory pathways responsible for vascular
stability. Therefore, we aimed to estimate SOCS-3 levels in
2nd trimester pregnant females and correlate it with
blood pressure. A case control study recruiting (n=111)
females was conducted at the Aga Khan University. They
were classified as pregnancy induced hypertensives or
normotensive as per American College of Obstetricians
and Gynecologists Guidelines. Weight, Body mass index,
lipid profile and blood glucose were recorded while
SOCS-3 was measured by ELISA. Higher SOCS-3 levels
were seen in hypertensive group (30 pg/ml) versus
normotensive (16 pg/ml). Both Systolic & diastolic blood
pressure (r=0.520; p<0.001) (r=0.490; p<0.001) showed an
independent significant positive correlation with SOCS-3
level. It is safe to suggest that SOCS-3 has an association
of causing high blood pressure. However, more research
needs to be conducted to establish a mechanism and
chronological order to these events in a pregnant female.
Keywords: Hypertension, Pregnancy, SOCS-3, Obesity.

Introduction
Pregnancy induced hypertension (PIH) is the
development of new hypertension in a pregnant woman
20 weeks after gestation without the presence of protein
in the urine or other signs of preeclampsia.PIH
complicates around 6-10% of all pregnancies around the
world.1 These complications include pre-eclampsia,
nervous system dysfunction, pulmonary oedema,
elevated liver enzymes during pregnancy in the mother2
and for the foetus, it may lead to intrauterine growth
restriction (IUGR), premature birth or even death in
extreme conditions.1 In Pakistan itself, the morbidity and
mortality are significantly higher — of 100 cases admitted
for PIH, complications were seen in 98, one of them
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resulting in death due to inadequate antenatal
management.3,4
The underlying cause of gestational hypertension in
humans is commonly believed to be an improperly
implanted placenta, or abnormal levels of inflammatory
cytokines. The hypothesised mechanism by which PIH
occurs is that the pro inflammatory state seen in
pregnancy can lead to vascular damage and
hypertension. This can be accounted by multiple possible
factors, such as a low anti-oxidant/oxidant ratio, which
would suggest that reactive oxygen species are able to
cause more damage to the blood vessels in the pregnant
females.1 Some cases have been seen where there is
increased natural killer cell function (due to increased
production of stimulatory cytokines) which is the
potential cause for the damage that leads to the
development of high blood pressure.5
One such protein is called the Suppression of Cytokine
Signaling (SOCS) which has a family of eight members
(SOCS1-7 and CIS). These are modulators of the
inflammatory pathway, that act by inhibiting the
activation of Janus kinase-signal transducer and is
activator of transcription (JAK-STAT) pathway to transmit
their information into the cell nucleus. This is achieved by
three potential routes (a) inhibiting JAK proteins that
have been activated directly, (b) being a competitive
antagonist for STAT proteins, and (c) up regulating the
proteasome lists of the STAT complexes. In this way, SOCS
is said to be involved in the regulation of the

1,23rd

Figure-1A: Hypothetical diagram of SOCS 3 and its role in hypertension.
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inflammatory mediators, controlling the degree of the
adverse effect.6 Lately, additional roles are identified in
suppressing the inflammatory pathways in the immune
system and in cancer biology.7 Yet, the functional
importance of SOCS-3 in regulating vascular health is
largely unknown but may be taken as an upcoming
marker for metabolic diseases8 (Figure-1A). Therefore, we
aimed to estimate SOCS-3 levels in 2nd trimester
pregnant females and correlate the levels with blood
pressure.

Data was analysed by using SPSS version 23. Quantitative
variables were expressed as mean ± standard deviation.
The Mann Whitney U test was used to compare the level
of SOCS-3 between pregnant females, with and without
hypertension and chi square or Fischer extact test is
applied wherever applicable. The Spearman ranks
correlation was applied to test the association of SOCS-3
with hypertension and obesity. In all instances, a p value
of <0.05 was considered significant.

Subjects and Methods

Results and Conclusion

A case control study was conducted at the Aga Khan
University, Karachi from January 2017 till February 2018.
Inclusion criteria included pregnant females in their 2nd
trimester (13 to 27 weeks) between the ages of 20-35 years.
While females with any comorbid such as gestational
diabetes, twin pregnancies, chronic cardio metabolic illness
or infectious diseases such as HIV, HBV, HCV or females on
anti-inflammatory medication, were excluded from the
study. Furthermore, females with pre-existing hypertension,
and complicated cases were excluded from this study. The
sample size was calculated using the Open-Epi website,9
with 1:1 distribution of cases and controls, where
confidence level of 95%, power of 80%, least extreme odds
ratio (OR) of 2 and a pregnancy hypertension prevalence of
8% was chosen as this was the result according to
previously published data sources.10 The minimum sample
size calculated for this research was 106.More than 150
pregnant ladies were contacted from the outpatient clinics
and community health centre waiting room areas, and a
total of 111 females agreed to participate and were
recruited for this study. All the study participants gave a
written and informed consent to participate in the study.
Weight, height, BMI at the time of admittance, gestational
age, family history lipid, profile and blood glucose level were
recorded for all subjects. A blood pressure measurement
was performed on each subject and previous two blood
pressure readings were recorded from the subject's file. The
subjects were then classified for having pregnancy induced
hypertension (PIH) following the ACOG Guideline which
states that "A blood pressure of >140/90 mm Hg is
considered as PIH (n=50),11 and normotensive (n= 61) by
the convienient randomn technique. Written informed
consent was obtained from the participants and five
milliliters blood sample was collected after an overnight
fast. Serum was separated and stored for comparative
analysis. ELISA assays were used to detect SOCS-3 levels (kit
cat # H1415 by Glorybioscince, Belgium). The study was
approved by the Ethics and Review Committee of Aga Khan
University (ERC-4523-BBS-16).
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Statistical Analysis

The mean age and parity of the study subjects was on an
average, matched between the two groups (p>0.05).
Furthermore, obesity and lipid derangement are
confounding factors for hypertension, SOCS-3 is
associated with inhibiting insulin signaling which in turn
inhibits the lipid reabsorption into the adipose tissue and
liver.12 Therefore, in this study, we wanted to assess if
there was any lipid derangement along with the
disruption of SOCs-3 in the study subjects. No difference
in the lipid profile levels was observed, suggesting that
SOCs-3 may act as an independent marker for blood
pressure in pregnancy. However, hypertensive pregnant
females were obese and had a higher BMI compared to
normotensive females (p<0.05). Higher SOCS-3 levels
were seen in hypertensive group (30 pg/ml) versus
normotensive (16 pg/ml) (Table). When we stratified ours
groups based on BMI in order to assess the difference in
SOCS-3 levels; higher levels were observed in
hypertensive group across all BMI categories (Table-1).
Lastly, we plotted a relationship curve between the
biomarker, BMI and blood pressure. Both Systolic blood
pressure (r=0.520; p<0.001) and diastolic blood pressure
(r=0.490; p<0.001) showed a significant positive
correlation with SOCS-3 level, whereas a non-significant
association was observed with BMI (r=0.351; p=0.101)
(Figure). The results of this study indicate that there is a
positive correlation between SOCS-3 and hypertension.
This signifies that SOCS-3 may play a role in the
pathogenesis of the disease, and hence opening a
possible area of research and treatment route for PIH.
Previous studies have shown that a low level of SOCS-3
was related to disease processes such as inhibition of
differentiation of epithelial to mesenchymal cells and
cellular proliferation in kidney proximal tubule cells.13
However, our results show a higher SOCS-3 level in
hypertensive individuals, suggests the possibility that
SOCS-3 is being produced as a result of the inflammatory
environment during pregnancy and obesity in an attempt
to limit the inflammatory damage and maybe prevent the
catastrophic effects of hypertension. We cannot comment
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Table: Parameters of study subjects.
Variable

Normotensive
(n= 61)

Hypertensive
(n= 50)

p value

Age (year)
Weight (kg)
BMI (kg/m2)
Gestational Age (weeks)
Parity

26.59 ± 5.26
65.52 ± 13.40
25.69 ± 4.94
26.22 ± 2.15
40 (65.57)
21 (34.42)
5 (8.19)
56 (91.80)
93.32 ± 26.02
144.32 ± 58.25
50.96 ± 8.613
110.98 ± 10.44
70.00 ± 8.63
16.75 ± 7.402

27.21± 5.93
72.37 ± 16.11
27.95 ± 5.79*
27.17 ± 1.24
33 (66.0)
17 (34.0)
3 (6.00)
47 (94.0)
91.53 ± 19.56
147.62 ± 60.04
51.65 ± 6.98
148.75 ±16.60*
101.25 ±10.99*
30.43 ± 13.505*

0.602
0.032
0.050
0.848
0.648

Primi
Multi
LSCS
SVD

Previous mode of delivery
FBG (mg/dl)
TAG (mg/dl)
HDL (mg/dl)
SBP (mmHg)
DBP (mmHg)
SOCs3 (pg/ml)

0.843
0.733
0.798
0.698
<0.001
<0.001
<0.001

Stratification of subjects based on Hypertension and BMI category
Variable

SOCS-3 (pg/ml)

Normal Weight HTN
(n=20)

Overweight HTN
(n=12)

Obese HTN
(n=18)

24.46 ±3.48

37.34 ± 2.39

26.50 ±2.91

Normal Weight Normotensive Overweight Normotensive Obese Normotensive
(n=21)
(n=10)
(n=30)
12.61± 6.53

14.25 ±4.65

20.49 ±6.93

Where: BMI (Body mass index), FBG (fasting blood glucose), TAG (triglyceride), HDL (high density lipoprotein), SBP (systolic blood pressure) DBP (diastolic blood pressure). Values expressed as Mean ± SD or
absolute number with percentage in parenthesis. Groups compared by.

Figure-: Correlation of SOCS-3 with
blood pressure and BMI.
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on the role of SOC-3 an anti inflammtory marker as we
were limited to measuring cytokine levels in the study
subjects due to budget constraints. Yet more
observations and information about SOCS-3 as a chemical
(as to the exact effects in the body, the production and
the potential side effects it's administration may have)
would be required before considering this route. It is
important to note that only a few studies were available
on SOCS-3, obesity,14 diabetes and inflammatory
cytokines.15 However, no articles were available that
established associated levels of SOCS-3 with obesity or
hypertension in pregnant females. Once a relationship
between the two is established, levels of SOCS-3 can be
monitored and changed through intervention to avoid
comorbids like hypertension and other associated
complications.
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